To compare the efficacy and safety of the recommended usual starting and next highest doses of ezetimibe/ simvastatin and atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia.
PATIENTS AND METHODS:
This double-blind, multicenter study (June 22 to December 7, 2005) consisted of adult patients randomized to the recommended usual starting (ezetimibe/simvastatin, 10/20 mg/d, vs atorvastatin, 10 or 20 mg/d) or next highest (ezetimibe/simvastatin, 10/40 mg/d, vs atorvastatin, 40 mg/d) doses. Efficacy end points included percent changes from baseline in low-density lipoprotein cholesterol (LDL-C) levels (primary) and proportion of patients attaining LDL-C levels less than 70 mg/dL (secondary).
RESULTS:
A total of 1229 patients participated in the study. Significantly greater mean reductions were found in LDL-C levels with ezetimibe/simvastatin, 10/20 mg/d (-53.6%; 95% confidence interval [CI] , -55.4% to -51.8%), than with atorvastatin, 10 mg/d (-38.3%; 95% CI, -40.1% to -36.5%; P<.001))or 20 mg/d (-44.6%; 95% CI, -46.4% to -42.8%; P<.001), and with ezetimibe/simvastatin, 10/40 mg/d (-57.6%; 95% CI, -59.4% to -55.8%), vs atorvastatin, 40 mg/d (-50.9%; 95% CI, -52.7% to -49.1%; P<.001). Ezetimibe/simvastatin was also superior to atorvastatin in attainment of LDL-C levels less than 70 mg/dL (P<.001 for all dose comparisons). Significantly better improvements with ezetimibe/simvastatin than with atorvastatin (P≤.001) were observed for total cholesterol, high-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol. Ezetimibe/ simvastatin, 10/20 mg/d, reduced high-sensitivity C-reactive protein and triglyceride levels significantly more than atorvastatin, 10 mg/d (P=.02), with comparable reductions at other doses. Incidences of clinical adverse events, including serious drug-related and prespecified gastrointestinal-, gallbladder-, and hepatitis-related allergic reactions or rash events, and laboratory adverse events, including repeated elevation of hepatic transaminases or creatine kinase levels, were similar for both treatments.
CONCLUSION: Ezetimibe/simvastatin provided additional lipidmodifying benefits over atorvastatin monotherapy at the recommended usual starting and next highest doses in patients with type 2 diabetes. Both treatments were generally well tolerated.
Mayo Clin Proc. 2006; 81(12) :1579-1588 ADA = American Diabetes Association; CAE = clinical adverse event; CHD = coronary heart disease; CI = confidence interval; CVD = cardiovascular disease; HDL-C = high-density lipoprotein cholesterol; hsCRP = highsensitivity C-reactive protein; LAE = laboratory adverse event; LDL = lowdensity lipoprotein; LDL-C = LDL cholesterol; NCEP ATP III = National Cholesterol Education Program Adult Treatment Panel III; ULN = upper limit of normal I ndividuals with type 2 diabetes mellitus are at increased risk for coronary heart disease (CHD).
1,2 High rates of cardiovascular disease (CVD)-related morbidity and mortality in this population are attributed in part to lipid abnormalities, typified by increased triglyceride levels, low high-density lipoprotein cholesterol (HDL-C) levels, and increased numbers of small dense low-density lipoprotein (LDL) particles. 3, 4 Lipid management can reduce major CHD events associated with type 2 diabetes as indicated by meta-analysis of several randomized clinical trials based on a composite of major CHD events, including CHD death, nonfatal myocardial infarction, or myocardial revascularization procedures. 2, 3, 5 The American Diabetes Association (ADA), National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), and the American Heart Association/American College of Cardiology consider aggressive lipid-lowering measures to be an integral aspect of the care of patients with type 2 diabetes. 2, 6, 7 Lifestyle modification and glucose control can improve general lipid profiles in these patients, but supplementary pharmacological intervention, primarily directed at LDL cholesterol (LDL-C), is recommended for most patients. In particular, the importance of statins in lowering plasma LDL-C levels to achieve reductions in CVD events has been well demonstrated in patients with established CHD and CHD-equivalent risk, including those with type 2 diabetes. 5, 8, 9 The ADA and NCEP ATP III guidelines identify the primary goal of lipid-related therapy as an LDL-C level less than 100 mg/dL for patients with type 2 diabetes. The ADA further recommends that LDL-C levels should be reduced 30% to 40% from baseline through statin therapy in patients with type 2 diabetes older than 40 years or with For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings. For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings. overt CVD, 2 and both the ADA and the NCEP ATP III identify an LDL-C level of less than 70 mg/dL as an optional target for patients with type 2 diabetes who are at high risk for CVD. 2, 6 Although LDL-C is the main target of lipid-modifying intervention in type 2 diabetes, raising HDL-C levels to more than 40 mg/dL in men and more than 50 mg/dL in women and lowering triglyceride levels to less than 150 mg/dL have been proposed by the ADA for highrisk patients. 2 The NCEP ATP III 6 also recommends targeting non-HDL-C in hypertriglyceridemic individuals after achievement of LDL-C goal and then raising HDL-C levels as a third priority. 6 The challenge of attaining more stringent LDL-C targets has stimulated research into possible new combinations of lipid-lowering drugs. 10 Ezetimibe, a first-in-class inhibitor of cholesterol absorption, has emerged as an effective agent for combined use with statins to achieve the recommended levels of LDL-C. 2, 6 Specifically, ezetimibe in combination with simvastatin, approved by the US Food and Drug Administration as a single-tablet formulation (Vytorin, Merck/Schering-Plough Pharmaceuticals, West Point, Pa), has proved highly effective in reducing LDL-C levels through its dual inhibition of cholesterol absorption and biosynthesis. [11] [12] [13] [14] [15] [16] Given the increasing prevalence of type 2 diabetes and projected growth in the numbers of patients expected to develop this disease in the next 20 years, 17 the identification of effective lipid-lowering therapy for these patients is important. Currently, most ezetimibe/simvastatin (84%) and atorvastatin (75%) prescriptions are accounted for by the recommended usual starting (ezetimibe/simvastatin, 10/20 mg/d, or atorvastatin, 10 or 20 mg/d) 
PATIENTS AND METHODS
This randomized, double-blind, parallel-group study recruited patients with type 2 diabetes (aged 18-80 years) with hemoglobin A 1c levels of 8.5% or less at 147 participating centers in the United States. Study conduct conformed to national and international standards regulating clinical studies in humans and was initiated on June 22, 2005 , and completed on December 7, 2005 . The protocol (077) was approved by appropriate institutional review boards, and all patients provided informed written consent.
After a 3-to 5-week washout period of current lipidlowering medications, patients maintained their ADA or similar glucose-and cholesterol-lowering diets during a 4-week placebo run-in. Patients who had an LDL-C level greater than 100 mg/dL and a triglyceride level less than 400 mg/dL in the third week of the run-in and who satisfied other eligibility criteria were randomized via an interactive voice response system to the recommended usual starting doses of ezetimibe/simvastatin (10/20 mg/d) vs atorvastatin (10 or 20 mg/d) or the next highest doses of ezetimibe/ simvastatin (10/40 mg/d) vs atorvastatin (40 mg/d). Treatment was administered daily for 6 weeks; the ADA-compatible diet was continued for the study duration. Patients were randomized according to LDL-C levels obtained after washout and placebo run-in periods (Table 1) . 18 Baseline efficacy parameters were the average of measurements made 1 week before and on the day of the start of active therapy. All lipid measurements were made after a fast of at least 12 hours.
Safety was assessed by monitoring clinical adverse events (CAEs) and laboratory adverse events (LAEs). Prespecified clinical safety variables included gastrointestinal-, gallbladder-, and hepatitis-related adverse events, plus allergic reactions and rash; laboratory safety variables included serum alanine aminotransferase, aspartate aminotransferase, and creatine kinase levels. Patients undergoing the same treatments were pooled across dose groups for assessment of safety and tolerability.
Efficacy outcomes were assessed after 6 weeks of active treatment in the modified intent-to-treat population based on all randomized patients who had valid baseline measurements and at least 1 valid postbaseline measurement. The primary efficacy end point was the percent reduction from baseline in LDL-C level. The secondary efficacy end point was the proportion of patients who attained the NCEP ATP III recommended LDL-C level of less than 70 mg/dL for very high-risk patients. Other efficacy measures included the proportion of patients who attained the NCEP ATP III LDL-C target of less than 100 mg/dL; percent change from baseline in total cholesterol, HDL-C, non-HDL-C, and triglyceride levels; and changes in high-sensitivity C-reactive protein (hsCRP).
Primary statistical hypotheses were the comparison of percent reductions in LDL-C levels at 6 weeks after treatment at the recommended usual starting doses (ezetimibe/ simvastatin, 10/20 mg/d, vs atorvastatin, 10 or 20 mg/d) or the next highest doses (ezetimibe/simvastatin, 10/40 mg/d, vs atorvastatin, 40 mg/d). Differences were tested using the Hochberg procedure 19 with α=.05 for type I error. Treatment comparisons were based on an analysis of variance model with terms for treatment and baseline LDL-C stratum. This model was used to examine the percent change from baseline in other efficacy variables. The triglyceride and hsCRP levels were assessed by nonparametric analysis of variance of the ranks based on normal scores, and medians are reported rather than means. Patients who attained an LDL-C level of less than 70 mg/dL and less than 100 mg/dL were analyzed by a logistic regression model with terms for treatment and baseline LDL-C stratum. A 2-tailed P≤.05 was specified for statistical significance.
For the primary study hypothesis, more than 90% power was expected for 205 evaluable patients per treatment group, assuming treatment differences of 10% (ezetimibe/ simvastatin, 10/20 mg/d, vs atorvastatin, 10 mg/d) and 5% (ezetimibe/simvastatin, 10/20 mg/d, vs atorvastatin, 20 mg/d, and ezetimibe/simvastatin, 10/40 mg/d, vs atorvastatin, 40 mg/d), 14% within-group SD, and an α of .05 (2-sided) .
The safety analysis of CAEs was based on all randomized patients who received at least 1 dose of study medication.
Analysis of LAEs was based on all patients with at least 1 postbaseline laboratory assessment. The Fisher exact test was used for prespecified treatment group comparisons.
RESULTS

PATIENT DEMOGRAPHICS
Of 2299 patients screened, 1229 were randomized to treatment. Baseline characteristics of the randomized patients were similarly distributed among treatment groups (Table  1) . The LDL-C baseline values were comparable across the prespecified strata, with a mean LDL-C level of 145 mg/dL (Table 1) . Metabolic syndrome was widely prevalent (86.6%). All but 1 patient in the study (Table 1) had type 2 diabetes, 15.1% of the patients had prior CHD and type 2 diabetes, and 11.6% had other forms of atherosclerotic vascular disease. Of the randomized patients, 1198 (97.5%) †For patients who completed active treatment, BMI was determined at weeks -4, -1, 0, and 6. ‡Metabolic syndrome is defined as having ≥3 of the following 5 characteristics: (1) waist circumference >102 cm in males or >88 cm in females; (2) triglyceride level of >150 mg/dL; (3) high-density lipoprotein cholesterol level <40 mg/dL in males or <50 mg/dL in females; (4) blood pressure >130/85 mm Hg or taking antihypertensive medication; and/or (5) fasting glucose level >100 mg/dL or diabetic. 18 §Patients with CHD and CHD equivalent risk may be in more than 1 category of CHD, other forms of atherosclerosis, and diabetes (in which diabetes is defined as a baseline fasting glucose level ≥126 mg/dL on ≥2 occasions, a diagnosis of diabetes, or use of antidiabetic medications). ⁄⁄Other forms of atherosclerosis are peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid artery disease, transient ischemic attack, and stroke. were included in the modified intent-to-treat population (480 in the ezetimibe/simvastatin group and 718 in the atorvastatin group) for efficacy analysis (Figure 1 ).
EFFICACY END POINTS
Mean percent reductions in LDL-C levels from baseline were significantly greater with the recommended usual starting dose of ezetimibe/simvastatin, 10/20 mg/d (-53.6%; 95% confidence interval [CI], -55.4% to -51.8%), compared with atorvastatin, 10 and 20 mg/d (-38.3%; 95% CI, -40.1% to -36.5%; and -44.6%; 95% CI, -46.4% to -42.8%, respectively; P<.001) ( Table 2 and Figure 2 ). At the next highest dose, the mean percent LDL reductions were -57.6% (95% CI, -59.4% to -55.8%) and -50.9% (95% CI, -52.7% to -49.1%) for ezetimibe/simvastatin, 10/40 mg/d, and atorvastatin, 40 mg/d, respectively (P<.001).
A significantly greater percentage of patients treated with ezetimibe/simvastatin, 10/20 mg/d (59.7%; 95% CI, 53.5% to 65.9%), attained levels of LDL-C less than 70 mg/dL compared with atorvastatin, 10 and 20 mg/d (Figure 3, top) . Similarly, 74.4% (95% CI, 68.9% to 79.9%) of patients treated with ezetimibe/simvastatin, 10/40 mg/d, had attained LDL-C levels of less than 70 mg/dL compared with 55.2% (95% CI, 48.9% to 61.5%) with atorvastatin, 40 mg/d (P<.001). Consistent with the whole cohort, higher proportions of patients in the CHD subgroup also attained LDL-C levels less than 70 mg/dL with ezetimibe/simvastatin than atorvastatin (Figure 3 , middle). The interaction of treatment by CHD classification was not statistically significant (P=.11). Similarly, the percentage of patients who attained a target LDL-C level of less than 100 mg/dL with ezetimibe/ simvastatin, 10/20 mg/d (90.3%; 95% CI, 86.5% to 94.1%), was significantly greater than with atorvastatin, 10 and 20 mg/d (70.0%; 95% CI, 64.2% to 75.8%; P<.001; and 82.1%; 95% CI, 77.2% to 87.0%; P=.007; respectively) (Figure 3, bottom) . Attainment rates for ezetimibe/ simvastatin, 10/40 mg (93.4%; 95% CI, 90.3% to 96.5%), and atorvastatin, 40 mg/d (88.8%; 95% CI, 84.8% to 92.8%), did not differ significantly (P=.07).
ADDITIONAL EFFICACY END POINTS
At all doses, the increases from baseline in HDL-C levels were significantly greater with ezetimibe/simvastatin compared with atorvastatin (P≤.001) ( Table 2 ). Ezetimibe/ simvastatin was also superior to atorvastatin in lowering plasma total cholesterol and non-HDL-C levels (P<.001) at all prespecified comparisons. Ezetimibe/simvastatin, 10/ 20 mg/d, decreased levels of hsCRP and triglycerides significantly more than atorvastatin, 10 mg/d (P=.02). At the other dose comparisons, reductions in hsCRP and triglyceride levels were comparable.
SAFETY AND TOLERABILITY
Clinical adverse events occurred in 98 patients (19.8%) in the ezetimibe/simvastatin groups and 166 patients (22.7%) *Data derived from patients in the modified intent-to-treat population, which included all randomized patients who had a valid baseline and at least 1 valid postbaseline measurement. HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol. †Percent changes from baseline and between-treatment differences are least squares means and differences in least squares means from an analysis of variance model, including terms for treatment and pretreatment LDL-C stratum. in the atorvastatin groups (Table 3) . No statistically significant differences were found in the frequency of any prespecified CAEs between the treatment groups, including drug-related and/or serious CAEs, CAEs leading to discontinuation, and CAEs related to the gastrointestinal tract, gallbladder, hepatitis, rash, or allergy. Eight patients discontinued participation in the study because of drugrelated adverse events, and no patient discontinued participation because of an adverse event that was both serious and drug related. One death occurred during the study: a patient treated with atorvastatin, 20 mg/d, died of chronic obstructive pulmonary disease (not considered drug related). Laboratory adverse events occurred in 8 patients (1.6%) in the ezetimibe/simvastatin group and 10 patients (1.4%) in the atorvastatin group. Drug-related LAEs occurred in 3 patients in both treatment assignments. No serious LAEs occurred, and no patients discontinued study participation because of an LAE.
No patient had a creatine kinase elevation 10 or more times the upper limit of normal (ULN), with or without muscle symptoms. A creatine kinase elevation 5 or more to less than 10 times the ULN occurred in 1 patient treated with ezetimibe/simvastatin, 10/40 mg/d, and 1 treated with atorvastatin, 20 mg/d. Consecutive elevations of alanine aminotransferase and/or aspartate aminotransferase to 3 or more times the ULN were observed in the atorvastatin treatment group in 2 patients at the end of the study and in 1 patient at the randomization visit who then discontinued participation in the study. None of the patients treated with ezetimibe/simvastatin experienced similar elevations.
DISCUSSION
In this study, ezetimibe/simvastatin was consistently superior to atorvastatin in reducing LDL-C levels at both the recommended usual starting and next highest doses in patients with type 2 diabetes and hypercholesterolemia. Ezetimibe/simvastatin reduced LDL-C levels by more than 50% from baseline at these doses, fulfilling the ADA recommendation of a 30% to 40% reduction from baseline. 2 This study also confirmed the superior attainment of LDL-C levels of less than 70 mg/dL in high-risk patients with ezetimibe/simvastatin vs atorvastatin and did so across a wider range of dosages than previously reported. 20 Thus, these results add to the clinical experience with ezetimibe/ simvastatin, affirming its effectiveness in the management of high LDL-C levels [11] [12] [13] 20, 21 and extending that finding to patients with type 2 diabetes.
The baseline mean level of LDL-C in this study (145 mg/dL) was similar to that reported elsewhere for patients with type 2 diabetes (approximately 150 mg/dL) 22 but was lower than in many previous trials of lipid-lowering therapy for all patients (approximately 170 mg/dL). Given this relatively low starting level, a high rate of attainment of the LDL-C target of less than 100 mg/dL was anticipated Eze/Sim better and confirmed (Figure 3, bottom) . A statistically greater attainment of this goal occurred with ezetimibe/simvastatin compared with atorvastatin at the recommended usual starting doses. The proportion of patients reaching an LDL-C level of less than 100 mg/dL with ezetimibe/simvastatin was near maximal at all doses (>90%); therefore, the intergroup difference diminished as the atorvastatin dose increased.
Achievement of large percent reductions in LDL-C was associated with significant reductions in major coronary events in the Heart Protection Study, which included 5963 patients with diabetes. 8 In that study, intense treatment of patients with 40 mg of simvastatin resulted in improvements in major CHD events regardless of baseline LDL-C levels, and the investigators concluded that a threshold had not been identified below which a further reduction of LDL-C levels confers additional benefit. 8 As such, the NCEP ATP III has recommended an optional target of less than 70 mg/dL for very high-risk patients with CVD, including diabetic patients with CVD. 6 Similarly, other studies of atorvastatin have demonstrated that aggressive treatment that lowers cholesterol levels to below currently recommended target thresholds is associated with additional clinical benefits in patients with type 2 diabetes. 22, 23 Thus, given the very high levels of CVD risk confronting patients with type 2 diabetes, aggressive management of LDL-C to reach levels less than 70 mg/dL may be warranted in type 2 diabetes patients with CVD.
Our data indicate that the attainment of this more exacting LDL-C level of less than 70 mg/dL in patients with type 2 diabetes and hypercholesterolemia is substantially greater with ezetimibe/simvastatin than with atorvastatin monotherapy at the recommended usual starting or next highest doses. Most patients attained LDL-C levels of less than 70 mg/dL at all doses of ezetimibe/simvastatin, including those with established CHD, who have been identified as candidates for the most aggressive LDL-C lowering. 2, 6 The success in attainment of this level of LDL-C contrasts with reports of other therapies, in which achieving an LDL-C level of less than 70 mg/dL was deemed difficult. 10, 24, 25 Diabetic dyslipidemia consists of increased numbers of small dense LDL particles, low HDL-C levels, and reciprocally elevated triglyceride levels. 3, 18, 26 In this study, statistically greater increases in HDL-C were achieved with FIGURE 3. Proportion of patients attaining low-density lipoprotein cholesterol (LDL-C) levels less than 70 mg/dL (top), LDL-C levels less than 70 mg/dL in the coronary heart disease subgroup (middle), and LDL-C levels less than 100 mg/dL (bottom). *P<.001 for specified between-treatment difference. †P=.007. Error bars indicate SEs. †Data derived from all patients randomized who had at least 1 dose of study drug. ‡Determined by investigators to be possibly, probably, or definitely drug related. §Data derived from patients with at least 1 postbaseline laboratory assessment.
ezetimibe/simvastatin at all doses compared with atorvastatin. Although higher levels of HDL-C have been shown to correlate with a lower risk of major coronary events, changes in HDL-C levels have not been demonstrated to predict risk. 27 Similarly, ezetimibe/simvastatin was significantly more effective at reducing non-HDL-C levels than atorvastatin at all dose comparisons. A significantly greater reduction in triglyceride levels was also obtained with ezetimibe/simvastatin, 10/20 mg/d, compared with atorvastatin, 10 mg/d (P=.02), and comparable reductions were observed at other studied doses. Lipoprotein ratios, including total cholesterol/HDL-C, LDL-C/HDL-C, apoB/apoA-1, and non-HDL/HDL-C, considered to be supplementary indicators of CVD risk, were also significantly improved by treatment with ezetimibe/simvastatin compared with atorvastatin (data not shown; P<.001 for all comparisons).
Elevated levels of the inflammatory marker protein hsCRP have been reported to predict the development of type 2 diabetes and risk of CVD in patients with (or without) type 2 diabetes, [28] [29] [30] although the clinical importance of this is still debated. 31 Previously, ezetimibe/simvastatin and atorvastatin were shown to comparably reduce hsCRP at all milligram-equivalent dose comparisons in patients with hypercholesterolemia. 12 In that study, a significantly greater proportion of patients also attained both LDL-C levels lower than 70 mg/dL and hsCRP levels lower than 2 mg/L with ezetimibe/simvastatin (10, 20, 40 , and 80 mg/d) compared with atorvastatin (10, 20, 40, and 80 mg/d; P≤.01) . 32 Similarly, in this study, ezetimibe/simvastatin and atorvastatin comparably reduced hsCRP levels at the higher dose comparisons, although at the lowest dose comparison, the reduction with ezetimibe/simvastatin was significantly greater compared with that of atorvastatin. Of note, the prognostic value of lowering hsCRP levels has yet to be demonstrated in outcome trials.
The safety and tolerability elicited by both study drugs in this study are consistent with previous reports. 8, 9, 13, 15, 16, [33] [34] [35] Overall rates of CAEs and discontinuations were low in both groups, and none of the serious CAEs were attributed to study treatment. A low incidence of elevated transaminase levels occurred in the atorvastatin group, but none were observed for ezetimibe/simvastatin. Although the incidence of serious CAEs was low in this relatively large study, it was neither powered nor of sufficient duration to accurately assess the prevalence of rare CAEs. Although both drugs were well tolerated, use of the lowest effective dose of a given product may be desirable to minimize the potential for adverse events.
CONCLUSION
This study demonstrated that ezetimibe/simvastatin administered at its recommended usual starting and next highest doses was superior to the corresponding doses of atorvastatin in its effects on a range of lipid and lipoprotein parameters. Thus, the dual cholesterol-lowering mechanism of ezetimibe/simvastatin provides an effective and well-tolerated option as first-line lipid-modifying therapy for patients with type 2 diabetes and hypercholesterolemia.
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